methyl-CpG binding domain protein 2Genealiases: DMTase · NY-CO-41
Q-omics provides the consensus-scored MBD2 profile across patient tissues and cancer cell-line models. MBD2 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, MBD2 is differentially expressed in 12, with the highest sampling consensus in THCA. Additionally, MBD2 RNA expression shows 19,869 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and THCA as cancer lineages where MBD2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MBD2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MBD2 survival associations across molecular data types. MBD2 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (3) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MBD2 RNA expression–survival associations across cancer types. High MBD2 expression shows unfavorable associations in ACC, UVM and LGG, but favorable associations in KIRC, OV and LUSC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for MBD2 RNA expression.
This table summarizes MBD2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 6. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for MBD2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MBD2 shows lower tumor expression in THCA and KICH and higher tumor expression in KIRC, LIHC, LUSC and CHOL. The THCA box plot shows higher MBD2 RNA expression in normal versus tumor tissue (log2 FC = −0.614, t-test p < 0.001).
This table shows molecular features associated with MBD2 in patient tissues and cancer cell lines. In patient samples, MBD2 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, MBD2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and BLOOD_Leukemia.
